LiveBreach Intelligence: data breaches, leaks & ransomware, tracked as they surfaceOngoing protection: GalaxyWarden →
Recent BreachesData breach tracker

Recent Breaches › DOCTUM PHARMACEUTICAL Κ. T. YIOKARIS & CO S.A. Listed by avaddon Ransomware Group

HIGH severityUnverified claimHow we verify

DOCTUM PHARMACEUTICAL Κ. T. YIOKARIS & CO S.A. Listed by avaddon Ransomware Group: Ransomware Claim — What’s Alleged & What To Do

RBRecent Breaches Breach Intelligence·September 9, 2021
DOCTUM PHARMACEUTICAL Κ. T. YIOKARIS & CO S.A. Listed by avaddon Ransomware Group

Reported September 9, 2021.

HIGH
Severity
September 9, 2021
Disclosed
ShareXLinkedInFacebookRedditWhatsAppTelegram

The DOCTUM PHARMACEUTICAL Κ. T. YIOKARIS & CO S.A. Listed by avaddon Ransomware Group (reported September 9, 2021) is an unverified claim; the data involved is undisclosed belonging to roughly unknown people. If you have an account with them, your information may now be circulating on the open web and with data brokers. Here’s exactly what happened, how to check if you were affected, and what to do next.

Severity & verification
HIGH severityUnverified claim
Data types not itemised.
Published on a ransomware group’s leak site — an unverified extortion claim until the named organization or credible reporting corroborates it.
Check your exposure
See every leak and listing tied to your email. We can’t confirm any single incident against the sources we search, so we won’t pretend to. 15-second check, no card, no account. Details go to your inbox.

By running your scan you agree to the Terms and Conditions and the Privacy Policy, and to GalaxyWarden emailing you the results of this scan.

DOCTUM PHARMACEUTICAL Κ. T. YIOKARIS & CO S.A. appeared on a ransomware group's leak site on 9 September 2021. The listing states that internal files were taken during a ransomware incident, though the number of people affected and the precise contents of any data remain unknown.

Incidents involving pharmaceutical companies raise questions about the handling of internal records that may include business information or details connected to individuals. When such material is claimed to have been removed, those whose information could be involved face uncertainty about how it might be used.

What happened

On 9 September 2021, DOCTUM PHARMACEUTICAL Κ. T. YIOKARIS & CO S.A. was listed on the leak site associated with the Avaddon ransomware group. The entry indicates that internal files were exfiltrated during a ransomware attack. No further details on the timing of the intrusion, the volume of data, or the method of access have been made public.

The group claims to have stolen internal data, but the organisation has not confirmed the listing or provided additional information about the incident. The number of individuals potentially affected is not disclosed.

Who is avaddon?

Avaddon was a ransomware operation active primarily between 2020 and 2021. Like several other groups operating at the time, it employed a double-extortion approach: encrypting systems and also threatening to publish stolen files if a ransom demand was not met. The group maintained a leak site where it listed victims and sometimes released samples of claimed data.

Avaddon's listings were presented as claims by the group itself. Independent confirmation of the contents or scale of any specific listing was not always available at the time the entries appeared.

Who is DOCTUM PHARMACEUTICAL Κ. T. YIOKARIS & CO S.A.?

DOCTUM PHARMACEUTICAL Κ. T. YIOKARIS & CO S.A. operates in the pharmaceutical sector. Companies of this type routinely maintain records related to manufacturing, research, regulatory compliance, and business operations. Some of these records can contain information about employees, partners, or patients.

A claim that internal files from such an organisation have been removed is consequential because pharmaceutical records often include data that is subject to regulatory protections and can be difficult to replace or secure once it leaves the organisation's control.

The information in question

The only detail provided is that internal files were allegedly exfiltrated. The exact categories of data are not disclosed. Organisations in this sector commonly hold employee records, supplier information, research documentation, and, in some cases, patient or clinical data.

Because the specific contents of the claimed files have not been published or verified, it is not possible to state which types of information, if any, were involved.

The real-world impact

Individuals whose information appears in internal pharmaceutical files could face risks such as misuse of personal details or attempts at fraud, depending on what the files contained. The absence of Reported Details means the scale of any such exposure cannot be assessed from public information.

For the organisation, the incident adds to operational disruption already associated with ransomware and creates uncertainty about future handling of similar records. No financial figures or confirmed outcomes beyond the listing itself have been reported.

What to do if you're exposed

Anyone concerned about possible exposure should monitor their financial and email accounts for unusual activity and consider placing fraud alerts with credit agencies where available. Changing passwords for any accounts that may be linked to the organisation is a standard first step.

Readers can run a free exposure scan of their email address against known breach data to check whether their information has appeared in previously published records.

AICompiled with AI assistance from public sources and published under our editorial standards.

Editorial & sourcing policy
Recent Breaches is a breach-monitoring service and news aggregator. We do not exfiltrate, host, purchase, or redistribute stolen data, and we do not hold the data claimed in leak-site listings. Incidents are compiled from publicly accessible sources and threat-intelligence platforms and are reported as claims attributed to their source. We promptly correct or remove material shown to be inaccurate — write to support@galaxywarden.com or press@recentbreaches.com.
Check if you’re exposed →

How this breach connects

Company

Attributed to

Method

CompanyDOCTUM PHARMACEUTICAL Κ. T. YIOKARIS & CO S.A. security record
88/100
DoxxScan™ · Low doxx risk
B 83Good record

1 reported incident on record.

See DOCTUM PHARMACEUTICAL Κ. T. YIOKARIS & CO S.A.’s full breach history →

More recent breaches

Intensive Care On-Line Network , Inc Listed by avaddon Ransomware GroupSeptember 9, 2021360 InStore Listed by avaddon Ransomware GroupSeptember 9, 2021NIJMAN / ZEETANK International Transport Sp. z o. o. Listed by avaddon Ransomware GroupSeptember 9, 2021HealthCare Global Enterprises Ltd Listed by avaddon Ransomware GroupSeptember 9, 2021

Latest breaches

Read GalaxyWarden’s full analysis of the DOCTUM PHARMACEUTICAL Κ. T. YIOKARIS & CO S.A. Listed by avaddon Ransomware Group →

Source: threat-actor leak-site listing

Publicly posted by avaddon — unverified claim, pending independent verification

Breach listings — particularly those originating from ransomware or leak sites — are third-party claims that may be unverified, incomplete, or inaccurate. A listing does not by itself confirm that a breach occurred or that any specific data was exposed. Severity is an automated assessment, not a definitive rating. Verification status is shown where available.

Attributions to threat groups and methods reflect public reporting and, in some cases, unverified claims made by the groups themselves; they may be incomplete or later revised. Recent Breaches and GalaxyWarden are independent and are not affiliated with, and do not endorse, any company or group named on this page. This information is aggregated from public sources for awareness only and is not legal, security, or investment advice.

ShareXLinkedInFacebookRedditWhatsAppTelegram